Trials / Recruiting
RecruitingNCT07324616
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Hepatic Function
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Edgewise Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDG-7500 | Single dose of EDG-7500 |
Timeline
- Start date
- 2026-01-26
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2026-01-07
- Last updated
- 2026-03-09
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07324616. Inclusion in this directory is not an endorsement.